Professional Documents
Culture Documents
Stephen Matlin
Executive Director
Global Forum for Health Research
Geneva
Biomedical research Health policy and systems Social sciences and Operational
research behavioural research research
Understanding the
biological nature of Understanding how to test, scale-up and follow through the introduction of
diseases; creating interventions and optimize their benefits
products to prevent or
treat disease states
Innovation
Impact
2. health
3. research
e.g. Commitments
1. Each economically advanced country will progressively increase its
official development assistance to the developing countries and will
exert its best efforts to reach a minimum net amount of 0.7 per cent of
its gross national product at market prices by the middle of the
decade.
Adopted: UN General Assembly 1970
Reinforced: Monterrey Consensus on Financing for Development 2002
Timetables: by 2015, set by many EU countries since 2002
e.g. Aspirations
2. The Ministers of Health and Heads of Delegation (of 14 African
countries) urge:
9.iii Global Health Initiatives and development agencies to devote at
least 5% of their overall health investment portfolio to support research
capacity of countries, dissemination of research findings and
management of knowledge.
Recommended: Accra Communiqué: High Level Ministerial Meeting on
Health Research for Disease Control and Development.
Accra, Ghana 17th June 2006
A All Countries
A-1 National R&D total investment as a % GDP
A-2 National R&D for health as % GDP
A-3 National R&D for health as % national health investments
A-4 National R&D for health as % total R&D
B High-income countries
B-1 Gap between actual ODA and commitment to invest 0.7% of GNI on ODA
B-2 Gap between actual annual increase in ODA and commitment to double aid
between 2005 and 2010 - an extra $50 billion worldwide and $25 billion for Africa
B-3 Gap between actual ODA investments in R&D for health and target to invest 5% of
health ODA in R&D for health
Targets
10
12
14
0
2
4
6
8
France
Germany
UnitedKingdom
Netherlands
Italy
Sweden
Spain
Norway
Denmark
Belgium
Switzerland
Austria
Net ODA (2002)
Finland
Ireland
Portugal
Greece
ODA spending by country
UnitedStates
Japan
Canada
Australia
New_Zealand
because health equity is a priority
Development cooperation (ODA)
Central government
Universities
Research institutions
Research councils
Nongovernmental organizations
Foundations/charities/trusts
Companies
Partnerships/Initiatives
Public-private partnerships
Researchers worldwide
DAC members’ total ODA from 1980
in 2006 US$ and as a share of GNI
0.40 80
0.30 60
0.20 40
0.10 20
0.00 0
1980 1985 1990 1995 2000 2005
Global Forum for Health Research, Monitoring Financial Flows for Health Research, 2008
because health equity is a priority
OECD 2005: www.oecd.org/dataoecd/34/26/36418606.pdf
because health equity is a priority
Comparison of 2005 ODA to the 0.7% of GNI target, for the G7 Countries
Canada
ODA below target
Italy Gap to target 0.7% GNI
France
Germany
United Kingdom
Japan
United States
0 10 20 30 40 50 60 70 80 90
ODA (actual and target), in billions US$
Global Forum for Health Research, Monitoring Financial Flows for Health Research, 2008
because health equity is a priority
Quality-adjusted aid
www.cgdev.org
because health equity is a priority
Aid flows
2002
$58 billion total aid flows from rich countries to poor ones
2003
Tanzania declared a four-month “mission holiday”,
receiving only the most urgent visits by donors
Foreign Policy, Ranking the Rich 2004
We reaffirm the commitments made at Rome to harmonise and align aid delivery….
especially in the following areas:
i. Strengthening partner countries’ national development strategies and associated
operational frameworks
ii. Increasing alignment of aid with partner countries’ priorities, systems and procedures
and helping to strengthen their capacities.
iii. Enhancing donors’ and partner countries’ respective accountability to their citizens and
parliaments for their development policies, strategies and performance.
iv. Eliminating duplication of efforts and rationalising donor activities to make them as cost-
effective as possible.
v. Reforming and simplifying donor policies and procedures to encourage collaborative
behaviour and progressive alignment with partner countries’ priorities, systems and
procedures.
vi. Defining measures and standards of performance and accountability of partner country
systems in public financial management, procurement, fiduciary safeguards and
environmental assessments, in line with broadly accepted good practices and their quick
and widespread application.
www.oecd.org/dataoecd/11/41/34428351.pdf
"Now because of all this changing prices, it has gone up to at least 62 billion
dollars now," Ban said. "First of all, G8 countries should implement their
commitment."
OECD-DAC Database: ‘Health ODA’ aggregates three Creditor Reporting System sectors:
(1) Health (2) Population Policies/Programmes & Reproductive Health (3) Water Supply/Sanitation
Kaiser Family Foundation www.kff.org/hivaids/upload/7679_02.pdf
OECD-DAC Database: ‘Health ODA’ aggregates three Creditor Reporting System sectors:
(1) Health (2) Population Policies/Programmes & Reproductive Health (3) Water Supply/Sanitation
Kaiser Family Foundation www.kff.org/hivaids/upload/7679_02.pdf
1000
1200
1400
1600
1800
200
400
600
800
0
Germany
France
United Kingdom
Italy
Spain
Netherlands
Belgium
Poland
Switzerland
Sweden
Greece
Austria
Portugal
Norway
Denmark
Total Expenditure on Health 2003
Czech Republic
Hungary
Romania
Finland
Ireland
Health expenditures: 2003
Slovenia
Iceland
Slovak_Republic
United_States
Japan
Canada
Australia
New_Zealand
because health equity is a priority
Land area
www.worldmapper.org
Targets
Tunis ia
Sudan
Senegal
Niger ia
Mozambique
Mali
Kenya
Ghana
Ethiopia
Egypt
Côte d'Ivoir e
Cape Ver de
Bots wana
Alger ia
0 2 4 6 8 10 12 14 16 18
Health as % governm ent expenditure 2003
Ic e la nd
S witze rla nd
1.0 1.0
0.9 0.9
S we de n
Expe nditure on health R&D as % of GDP
0.8 0.8
0.7 De nm a rk 0.7
0.6 US A 0.6
UK
0.5 Be lgium 0.5
S inga pore
C ana da
0.4 0.4
F ra nc e J apa n F inla nd
Aus tria Ge rm a ny
0.3 0.3
Ne the rla nd
Hunga ry
S pa in Ire la nd
Turke y Ita ly Norway
0.2 0.2
C ze c h R .
S outh Af ric a Kore a
P a na m a C uba P ortuga l
0.1 0.1
Arge ntina P oland
S lov a k R .
Gre e c e Me xic o Bra zil
Luxe m bourg
Trinidad R us s ia C hina
S lov e nia
0.0 0.0
0.0 1.0 2.0 3.0 4.0
10
Sweden
Switzerland
9
Health R&D as % of national health expenditure
Denmark
UK
6
Belgium
5 Finland
Japan
Canada
4 USA
Turkey
Austria France Hungary
Israel
Germany
3 Netherland
Ireland Spain
2
2% target
South Af rica for LMICs
Cuba Panama
Poland
Venezuela
1 PortugalSlov akia
China India MexicoRomania
Brazil
Argentina
Russia Luxemb. Greece
Trinidad
Slov enia
0
0 5 10 15 20 25 30 35
because health equity is a priority
Health R&D as % of total R&D expenditure
Global health R&D expenditures
180
160.3
160
140 51%
125.8 private
Health R&D expenditure
120
41%
105.9 48% public
private
100
48%
84.9 private 8%
45% not
80 48%
public for
private 44% profit
55.8 public
60 7%
not
45%
8% for
public
not profit
40
30 for
7% profit
not
20 for
profit
0
1986 1992 1998 2001 2003 2005
Year
Global Forum for Health Research, Monitoring Financial Flows for Health Research, 2008
because health equity is a priority
Globalization of disease burdens
Deaths by cause and WHO region, 2002
100
% Group I
90
Communicable,
80
maternal,
perinatal and
70 nutritional
conditions
60
50 Group 2
Non-
40 communicable
diseases
30
20
Group 3
Injuries
10
0
AFRO AMRO EMRO EURO SEARO WPRO
Diseases:
• that are significant sources of mortality and morbidity
• for which there are few or no adequate interventions
(that are relevant to large, affected populations)
• that attract relatively little R&D funding
‘Very
neglected
diseases'
• Type III
Overwhelmingly or exclusively incident in developing countries
• Type II
Incident in rich and poor countries but with a substantial
proportion of the cases in poor countries
• Type I
Incident in both rich and poor countries, with large numbers of
vulnerable populations in each
City County
Rank Cause Death Rate % Cause Death Rate %
(1/100000) (1/100000)
1 Malignant Neoplasms 126.42 23.92 Malignant Neoplasms 119.66 23.70
2 Cerebrovascular 100.90 19.09 Cerebrovascular Disease 74.95 14.85
Disease
3 Heart Disease 99.36 18.80 Diseases of Respiratory 67.18 13.30
System
4 Disease of Respiratory 69.33 13.12 Heart Disease 63.36 12.54
System
5 Injury & Poisoning 31.14 5.89 Injury & Poisoning 33.50 6.63
6 Diseases of Digestive 17.13 3.24 Diseases of Digestive 14.21 2.81
System System
7 Endocrine, Nutritional & 14.91 2.82 Endocrine, Nutritional & 12.74 2.52
Metabolic Diseases Metabolic Diseases
8 Diseases of 9.52 1.81 Disease of Genitourinary 8.11 1.61
Genitourinary System System
9 Disease of Nervous 4.59 0.86 Disease Originating in 363.95 0.68
System the Perinatal Period
(1/100,000 live birth)
10 Disease Originating in 168.46 0.52 Pulmonary Tuberculosis 3.25 0.64
the Perinatal Period
Chronic diseases: the new epidemic
Cancer, Diabetes, Heart Disease, Stroke, Mental/Neurological Conditions
160.3
160
140 51%
125.8 private
Health R&D expenditure
120
41%
105.9 48% public
private
100
48%
84.9 private 8%
45% not
80 48%
public for
private 44% profit
55.8 public
60 7%
not
45%
8% for
public
not profit
40
30 for
7% profit
not
20 for
profit
0
1986 1992 1998 2001 2003 2005
Year
Global Forum for Health Research, Monitoring Financial Flows for Health Research, 2008
because health equity is a priority
Global health R&D expenditures
180
160
HICs 98% 160.3
120
41%
public
100 USA 53%
8%
80
NIH 43% not
for
profit
of global publicR&D, of which
60
NCDs 96%
HICs 50-60%
40
NCDs ?%
20
0
1986 1992 1998 2001 2003 2005
Year
Global Forum for Health Research, Monitoring Financial Flows for Health Research, 2008
because health equity is a priority
because health equity is a priority